Quest Diagnostics empowers people to take action to improve health outcomes.
Company Overview

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

 

Learn More

Latest News
08282024

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

08262024

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at...

08212024

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and CLEVELAND, Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics...

All Releases

Newsroom

Quest Blog - Empowering better health with diagnostic insights.
Media Coverage
07302024
The Wall Street Journal
Two blood tests you probably haven’t heard of might predict your risk of heart disease better than standard tests do. The first measures a protein called apolipoprotein B, or apoB for short, that contributes to artery-blocking plaque. The other test, for lipoprotein(a), measures a type of bad cholesterol. A growing number of specialists and primary care doctors say these tests can help give you a more precise and earlier indication of possible heart problems than more common tests for things like LDL, the best-known bad cholesterol marker. Up to 20% of patients with normal LDL cholesterol levels will have high levels of apoB, says Dr. Marc Penn, a cardiologist and a medical director at laboratory testing company Quest Diagnostics.
07302024
360Dx
Coming years could see a shift in clinical laboratory operations as developments in robotics and AI further streamline workflows and bring automation to new parts of the lab. In particular, labs and vendors are working to deploy "trackless" robotics and automation systems to supplement or replace traditional track-based total lab automation (TLA) systems, further reducing the human involvement required for lab workflows and in some laboratories eliminating it entirely. Quest is also moving toward a trackless automation strategy, said Aldana, noting that the company began seriously pursuing this approach this year using both equipment from outside vendors as well as systems developed internally. He said that while the effort is still in the early stages, the company aims to quickly roll out trackless automation tools across its labs.

All Coverage

Quest Diagnostics Health Trends™

Quest Diagnostics Health Trends™ is a series of reports from Quest Diagnostics on health conditions affecting a large number of Americans. Published in peer-reviewed journals, at scientific conferences and widely as a public service, the reports are designed to inform health care professionals, patients and policymakers about the status of the nation’s health.

 

See All

At A Glance...

More than 6,600 patient access points, the most extensive network in the U.S., including phlebotomists in physician offices and more than 2,250 of our own patient service centers. A medical and scientific staff of more than 600 M.D.s and Ph.Ds. Logistics capabilities, that include approximately 3,750 courier vehicles and 25 aircraft that collectively make tens of thousands of stops daily.

Media Resources

Journalists may contact Quest Diagnostics by emailing mediacontact@questdiagnostics.com